Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of XP19986 in SCI Spasticity
NCT00557973Phase 2Completed
- Sponsor
- XenoPort, Inc.
- Start
- Dec 2007
- Primary completion
- Apr 2009
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of arbaclofen placarbil in Spasticity (3 cohorts), sponsored by XenoPort, Inc. Primary endpoint: Maximum Ashworth score at Day 17. Started Dec 2007; status: completed.
02
Drugs
arbaclofen placarbil
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT00557973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557973.